Alzheimer's and Parkinson's Diseases
A Global Update of Market Trends & Opportunities
| Product Code | BIZ00397 |
| Publication Date | November 2009 |
| Publisher | BizAcumen |
| Product Type | Report |
| Pages | 262 |
| ISBN Number | not applicable |
Alzheimer's and Parkinson's Diseases
A Global Update of Market Trends & Opportunities
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two important segments in neurodegenerative disorders market. These disorders represent unmet medical needs, as well as under diagnosed categories. However, this unmet requirement offers substantial opportunities for next generation therapies. Though there is no curative medicine available at present, medications that provide partial relief from symptoms have gained momentum in the recent past. The industry has crossed some milestones in recent years, although major breakthroughs are still in pipeline.
These and other market data and trends are presented in "Alzheimer's and Parkinson's Diseases: A Global Update of Market Trends & Opportunities" by BizAcumen LLC. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
Contents
- 1.Methodology
- Study Reliability and Reporting Limitations
- Disclaimers
- Quantitative Techniques & Reporting Level
- 2.Outlook
- Current and Future Analysis
- 3.Neurodegenerative Diseases Market - A Brief Overview
- Key Brands in Ndd Market
- Factors Affecting Market
- Major Growth Drivers
- Major Growth Inhibitors
- Market Trends
- High Prevalence Rates Drive Market Growth
- Rapid Growth of Ageing Population
- Price Hikes and Government Caps
- Combination Therapy Gaining Ground
- Research & Development
- Future Holds Promise
- 4.Alzheimer's Market Overview
- A Peek into Anti-Ad Drug Market
- Impact of Dementia
- Epidemiology
- Patient Growth Drivers
- Demographics Spell Opportunities
- High Growth Rates for Ad Drugs
- The Impact of Aricept
- Epic of Nmdara
- Strengths
- Weaknesses
- Future Therapies
- How Successful Will The Late Stage Therapies Be?
- Alternative Drug Delivery Technologies Gaining Ground
- Transdermal Patch
- Domination of Acetyl Cholinesterase Inhibitors
- Dramatic Changes in Market Lie Ahead
- Advances in next-Generation Treatments
- Beta Amyloid Hypothesis
- Growth Drivers
- Ageing Baby Boomers Drive Ad Market
- New Hypothesis Enables Effective Treatment
- Unmet Medical Needs Drive Market Growth
- Growth Inhibitors
- Link with Other Aliments
- Misdiagnosis
- Patient Awareness
- Medical Refunds
- Competitive Landscape
- Pharmaceutical Majors Rule The Market
- Eisai/Pfizer
- Novartis
- Shire/Johnson & Johnson
- Forest
- Ipsen and Ucb
- Compounds in Pipeline
- There Are Many Compounds in Pipeline for The Treatment of Ad
- Outlook for Ad Drugs Market
- 5.Parkinson's Disease Market Overview
- An Alluring Market
- Prevalence
- Current Treatments
- New Medicines on The Horizon
- New Findings
- Product Launches through 2009
- Dominance of Dopamine Agonists
- Revival Revels in Other Anti-Pd Drugs Segment
- Comt Inhibitors Growing Fastest
- Key Market Drivers
- Rising Awareness Magnifies Patient Base
- Emergence of Dopamine Agonists as First Line Treatment Drives Market- Growth
- The Debut of Stalevo
- Unmet Clinical Needs Show Mammoth Prospects
- Key Market Inhibitors
- Limitations of Existing Medicines Inhibit Market Growth
- under-Diagnosis Restrains Market Potential
- Generic Competition from L-Dopa and Carbidopa Curbs Market Growth
- Restricted Term of Dopamine Agonists Usage Delays Market Growth
- 6.Product Facts
- 1. Anti-Alzheimer's Disease Drugs
- A. Cholinesterase Inhibitors
- B. Nmdara
- 2. Anti-Parkinson's Disease Drugs
- A. Dopaminergic Agents (Levodopa/ Carbidopa)
- B. Dopamine Agonists
- C. Other Pd Drugs (Include Comt Inhibitors, Moa-B Inhibitors, and Dopamine Amplifiers)
- I. Comt Inhibitors
- II. Mao-B Inhibitors
- III. Dopamine Amplifiers
- 7.Future Therapies
- Alzheimer's Disease
- Key Pipeline Products
- Phenserine
- Ropern
- Alzhemed
- Mem 1003
- Ampakine Compounds
- Other Key Pipeline Products for The Alzheimer's Disease- Treatment.
- Parkinson's Disease
- Key Pipeline Products
- Adenosine A2a Antagonist
- Spheramine®
- Safinamide
- O-1369
- Other Key Pipeline Products for The Parkinson's Disease Treatment.
- 8.New Findings
- Risedronate Minimizes Risk of Hip Fractures in Pd Patients
- Researchers Identify New Genes Responsible for Ad
- Researchers Establish A New Link between Loneliness and Ad
- Researchers Try to Identify Early Stages of Ad
- Sorl1 - The New Gene Found to Be Responsible for Ad
- 9.Corporate Developments
- Eisai Acquires Mgi Pharma
- Eli Lilly Begins Phase Iii Clinical Trial of Alzheimer's Disease Treatment
- Merz Licenses Anti-Alzheimer's Drug Technology from Tau
- Eisai Acquires Morphotek
- Transition Therapeutics Acquires Neuromedix
- Evotec Teams up with Boehringer Ingelheim
- Siemens Signs Partnership Agreement with Wyeth
- Digilab Receives Notice of Allowance for New Alzheimer's Biomarker
- Pfizer Joins Forces with Genizon
- Intellect Signs Licensing Agreement with Ibl
- Boehringer Ingelheim Signs R&d Agreement with Ablynx
- Avicena Teams up with Ninds for Phase Iii Trial of Pd-02
- Exelon Patch Gets Eu Approval
- 10.Major Players
- Boehringer Ingelheim (Germany)
- Bristol-Myers Squibb Co. (USA)
- Eisai, Inc. (USA)
- Eli Lilly and Company (USA)
- Forest Pharmaceuticals (USA)
- Glaxosmithkline Plc (UK)
- H. Lundbeck A/S (Denmark)
- Merz Pharmaceuticals Gmbh (Germany)
- Novartis Ag (Switzerland)
- Ortho-Mcneil Neurologics, Inc. (USA)
- Pfizer Inc (US)
- Roche (Switzerland)
- Shire Pharmaceuticals Group Plc (UK)
- Valeant Pharmaceuticals International (USA)
- 11.Global Market Analytics
- 12.The United States
- Ad Market Overview
- Approval of Cholinesterase Inhibitors for Mci to Drive Market
- Competitive Landscape
- Status of Ad Drugs
- New Products in Clinical Trials
- Prevalence
- Pd Therapies Market
- Levodopa/Carbidopa on Declining Spree
- Competition
- Patent Expiry Status
- Patent Expiry Status of Parkinson's Disease Drugs in The US
- New Brands and Pipeline Analysis
- 13.Canada
- 14.Japan
- 15.Europe
- A.Germany
- B.France
- C.The United Kingdom
- D.Italy
- E.Spain
- F.Rest of Europe
- 16.Rest of World
- Exhibits
- Table 1: Percentage Breakdown of Leading Drugs in The Global Neurodegenerative Disease Market -
- Table 2: World Alzheimer's Disease Prevalence by Country/Region for The Period 2007 - 2010: (Number of Patients in Thousands)
- Table 3: Alzheimer's Disease Prevalence in Top Seven Countries (US, Japan, Germany, France, UK, Italy, and Spain) for The Period 2007 - 2010 (Number of Patients in Thousands)
- Table 4: Percentage Breakdown of Leading Brands in The Global Anti-Alzheimer's Drug Market -
- Table 5: World Parkinson's Disease Prevalence by Country/Region for The Period 2007 - 2010 (Number of Patients in Thousands)
- Table 6: Global Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Region for The Period 2007-2015 (Sales in US$ Million)
- Table 7: Percentage Breakdown of Global Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Region for The Years 2008 &
- Table 8: Global Anti-Alzheimer's Disease Drugs Market by Region for The Period 2007-2015 (Sales in US$ Million)
- Table 9: Percentage Breakdown of Global Anti-Alzheimer's Disease Drugs Market by Region for The Years 2008 &
- Table 10: Global Anti-Alzheimer's Disease Drugs Market by Product Segment for The Period 2007-2015 (Sales in US$ Million)
- Table 11: Percentage Breakdown of Global Anti-Alzheimer's Disease Drugs Market by Product Segment for The Years 2008 &
- Table 12: Global Cholinesterase Inhibitors Market by Region for The Period 2007-2015 (Sales in US$ Million)
- Table 13: Percentage Breakdown of Global Cholinesterase Inhibitors Market by Region for The Years 2008 &
- Table 14: Global Nmdara (N-Methyl, D-Aspartate Receptor Antagonists) Market by Region for The Period 2007-2015 (Sales in US$ Million)
- Table 15: Percentage Breakdown of Global Nmdara (N-Methyl, D-Aspartate Receptor Antagonists) Market by Region for The Years 2008 &
- Table 16: Global Anti-Parkinson's Disease Drugs Market by Region for The Period 2007-2015 (Sales in US$ Million)
- Table 17: Percentage Breakdown of Global Anti-Parkinson's Disease Drugs Market by Region for The Years 2008 &
- Table 18: Global Anti-Parkinson's Disease Drugs Market by Product Segment for The Period 2007-2015 (Sales in US$ Million)
- Table 19: Percentage Breakdown of Global Anti-Parkinson's Disease Drugs Market by Product Segment for The Years 2008 &
- Table 20: Global Dopaminergic Agents Market by Region for The Period 2007-2015 (Sales in US$ Million)
- Table 21: Percentage Breakdown of Global Dopaminergic Agents Market by Region for The Years 2008 &
- Table 22: Global Dopamine Agonists Market by Region for The Period 2007-2015 (Sales in US$ Million)
- Table 23: Percentage Breakdown of Global Dopamine Agonists Market by Region for The Years 2008 &
- Table 24: Global Other Pd Drugs Market by Region for The Period 2007-2015 (Sales in US$ Million)
- Table 25: Percentage Breakdown of Global Other Pd Drugs Market by Region for The Years 2008 &
- Table 26: Percentage Breakdown of Leading Therapeutics by New Prescription in The North American Alzheimer's Disease Market -
- Table 27: Percentage Breakdown of Leading Brands by Prescription in The US Pd Therapeutics Market -
- Table 28: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in The US: 2007-2015 (Sales in US$ Million)
- Table 29: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in The US for The Years 2008 &
- Table 30: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Canada: 2007-2015 (Sales in US$ Million)
- Table 31: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Canada for The Years 2008 &
- Table 32: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Japan: 2007-2015 (Sales in US$ Million)
- Table 33: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Japan for The Years 2008 &
- Table 34: Percentage Breakdown of Leading Brands by New Prescription in The European Alzheimer's Disease Market -
- Table 35: Anti-Alzheimer's and Anti Parkinson's Disease Drugs Market by Region in Europe: 2007-2015 (Sales in US$ Million)
- Table 36: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Region in Europe for The Years 2008 &
- Table 37: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Europe: 2007-2015 (Sales in US$ Million)
- Table 38: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Europe for The Years 2008 &
- Table 39: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Germany: 2007-2015 (Sales in US$ Million)
- Table 40: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Germany for The Years 2008 &
- Table 41: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in France: 2007-2015 (Sales in US$ Million)
- Table 42: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in France for The Years 2008 &
- Table 43: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in The UK: 2007-2015 (Sales in US$ Million)
- Table 44: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in The UK for The Years 2008 &
- Table 45: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Italy: 2007-2015 (Sales in US$ Million)
- Table 46: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Italy for The Years 2008 &
- Table 47: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Spain: 2007-2015 (Sales in US$ Million)
- Table 48: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Spain for The Years 2008 &
- Table 49: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Rest of Europe: 2007-2015 (Sales in US$ Million)
- Table 50: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Rest of Europe for The Years 2008 &
- Table 51: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Rest of World: 2007-2015 (Sales in US$ Million)
- Table 52: Percentage Breakdown of Anti-Alzheimer's and Anti-Parkinson's Disease Drugs Market by Product Segment in Rest of World for The Years 2008 &
- Companies Profiled